Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05661734 · ClinicalTrials.gov registry record · Phase 3
A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain
A Phase 3 study, sponsored by Vertex Pharmaceuticals Incorporated.
- Completed
- Registry status
- Phase 3
- Development phase
- 258
- Enrollment target
NCT05661734 is a Phase 3 study that has completed, run by Vertex Pharmaceuticals Incorporated. The registered enrollment target is 258 participants.
The verdict
NCT05661734, a Phase 3 study, has completed, sponsored by Vertex Pharmaceuticals Incorporated.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 258 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
Interventions
- DRUG Suzetrigine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 258 participants |
| Start Date | 2023-01-09 |
| Est. Completion | 2023-12-12 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05661734
The ClinicalTrials.gov registry entry for NCT05661734 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 258 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Vertex Pharmaceuticals Incorporated, which has 191 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Suzetrigine is the first listed.
NCT05661734 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT05661734 about?
NCT05661734 is a clinical study titled "A Single-arm Study to Evaluate Safety and Effectiveness of VX-548 for Acute Pain". The purpose of this study is to evaluate the safety and effectiveness of VX-548 in treating acute pain.
What is the current status of trial NCT05661734?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 258 participants. The study started on 2023-01-09. Estimated completion is 2023-12-12.
What interventions are being tested in trial NCT05661734?
The interventions under investigation include: Suzetrigine (DRUG).
Who is sponsoring clinical trial NCT05661734?
This trial is sponsored by Vertex Pharmaceuticals Incorporated, which has 191 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.